How did cyclophosphamide become the drug of choice for lupus nephritis?

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 381-384

  Bargman, Joanne M ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Azathioprine; Cyclophosphamide; Lupus; Lupus nephritis; Outcomes

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY FAILURE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENAL CORTEX HORMONES; AZATHIOPRINE; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; HISTORY, 20TH CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

EID: 58449113886     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn640     Document Type: Review

References (17)

1. Donadio JV Jr, Holley KE, Ferguson RH et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151-1155
2. Lewis E. The treatment of lupus nephritis: revisiting Galen (editorial). Ann Intern Med 2001; 135: 296-298
3. Bargman J. Why are rheumatologists treating lupus nephritis? Nat Clin Prac Nephrol 2007; 3: 296-297
4. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311: 1528-1533
5. Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 1974; 17: 923-937
6. Decker JL, Klippel JH, Plotz PH et al. Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann Intern Med 1975; 83: 606-615
7. Decker JL, Steinberg AD, Reinertsen JL et al. NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med 1979; 91: 587-604
8. Carette S, Klippel JH, Decker JL et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983; 99: 1-8
9. Balow JE, Austin HA 3rd, Muenz LR et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 311: 491-495
10. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619
11. Chan TM, Li FK, Tang CS et al. Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162
12. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
13. Balow JE, Austin HA 3rd. Maintenance therapy for lupus nephritis - something old, something new. N Engl J Med 2004; 350: 1044-1046
14. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980
15. Tu K, Campbell NR, Chen Z et al. Thiazide diuretics for hypertension: prescribing practices and predictors of use in 194,761 elderly patients with hypertension. Am J Geriatr Pharmacother 2006; 4: 161-167
16. McKay DB, Josephson MA. Pregnancy after kidney transplantation. Clin J Am Soc Nephrol 2008; 3(Suppl 2): S117-S125
17. Houssiau F, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis. Arthritis Rheum 2002; 46: 2121-2131